Denali Therapeutics Inc. DNLI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 36.96% | -6.77% | -11.91% | -21.23% | -16.67% |
| Total Depreciation and Amortization | 21.02% | 31.79% | 52.97% | 64.72% | 1,999.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -223.45% | 19.63% | 26.93% | 72.90% | 57.05% |
| Change in Net Operating Assets | -900.14% | -167.01% | -150.06% | -99.12% | -53.50% |
| Cash from Operations | -11.67% | -24.15% | -12.80% | -18.67% | -9.69% |
| Capital Expenditure | 55.59% | 81.36% | 63.43% | 40.28% | -0.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -138.32% | -84.29% | -15.95% | 463.49% | 340.07% |
| Cash from Investing | -93.28% | -84.41% | -13.62% | 387.62% | 316.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.54% | 96.38% | 89.57% | 74.74% | 31.40% |
| Issuance of Common Stock | 10,093.80% | 6,596.50% | 5,466.41% | 79.01% | -98.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -151,634.17% | 100.00% |
| Cash from Financing | 6,151.56% | 1,810.70% | 2,187.98% | -60.93% | -101.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 540.85% | -11.37% | 15,876.67% | -33.35% | 103.24% |